Last reviewed · How we verify
carbon-14-[14C]-ANG-3777
carbon-14-[14C]-ANG-3777 is a Small molecule drug developed by Angion Biomedica Corp. It is currently in Phase 1 development. Also known as: Hepatocyte growth factor mimetic.
At a glance
| Generic name | carbon-14-[14C]-ANG-3777 |
|---|---|
| Also known as | Hepatocyte growth factor mimetic |
| Sponsor | Angion Biomedica Corp |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carbon-14-[14C]-ANG-3777 CI brief — competitive landscape report
- carbon-14-[14C]-ANG-3777 updates RSS · CI watch RSS
- Angion Biomedica Corp portfolio CI
Frequently asked questions about carbon-14-[14C]-ANG-3777
What is carbon-14-[14C]-ANG-3777?
carbon-14-[14C]-ANG-3777 is a Small molecule drug developed by Angion Biomedica Corp.
Who makes carbon-14-[14C]-ANG-3777?
carbon-14-[14C]-ANG-3777 is developed by Angion Biomedica Corp (see full Angion Biomedica Corp pipeline at /company/angion-biomedica-corp).
Is carbon-14-[14C]-ANG-3777 also known as anything else?
carbon-14-[14C]-ANG-3777 is also known as Hepatocyte growth factor mimetic.
What development phase is carbon-14-[14C]-ANG-3777 in?
carbon-14-[14C]-ANG-3777 is in Phase 1.
Related
- Manufacturer: Angion Biomedica Corp — full pipeline
- Also known as: Hepatocyte growth factor mimetic
- Compare: carbon-14-[14C]-ANG-3777 vs similar drugs
- Pricing: carbon-14-[14C]-ANG-3777 cost, discount & access